State Street Corp Galera Therapeutics, Inc. Transaction History

State Street Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.17 - $3.0 $2,108 - $37,200	12,400 Added 13.17%	106,564 $19,000
Q2 2023 Aug 14, 2023	BUY	$2.5 - $3.42 $28,500 - $38,988	11,400 Added 13.77%	94,164 $293,000
Q1 2023 May 15, 2023	BUY	$1.48 - $2.68 $79,920 - $144,720	54,000 Added 187.73%	82,764 $211,000
Q1 2022 May 16, 2022	BUY	$2.01 - $4.19 $5,828 - $12,151	2,900 Added 11.21%	28,764 $68,000
Q3 2021 Nov 15, 2021	BUY	$7.04 - $10.49 $69,696 - $103,851	9,900 Added 62.01%	25,864 $209,000
Q2 2021 Aug 16, 2021	SELL	$6.08 - $10.44 $680,820 - $1.17 Million	-111,977 Reduced 87.52%	15,964 $157,000
Q1 2021 May 17, 2021	BUY	$8.35 - $12.39 $56,780 - $84,252	6,800 Added 5.61%	127,941 $1.13 Million
Q4 2020 Feb 16, 2021	BUY	$8.02 - $12.81 $307,719 - $491,506	38,369 Added 46.36%	121,141 $1.24 Million
Q3 2020 Nov 10, 2020	SELL	$6.96 - $9.12 $18,437 - $24,158	-2,649 Reduced 3.1%	82,772 $748,000
Q2 2020 Aug 14, 2020	BUY	$7.14 - $14.41 $502,206 - $1.01 Million	70,337 Added 466.3%	85,421 $610,000
Q1 2020 May 11, 2020	BUY	$5.89 - $17.67 $88,844 - $266,534	15,084 New	15,084 $143,000

961K

Ticker GRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,821,600
Market Cap $2.15M
Description
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical tria...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.